ALPS Overview

Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. The Company has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The Company provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. It operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.

Wall Street analysts forecast ALPS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALPS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Alps Group Inc revenue for the last quarter amounts to -317.43K USD, decreased -32.41

Alps Group Inc. EPS for the last quarter amounts to -270408.00 USD, decreased -59.87

Alps Group Inc (ALPS) has 26 emplpoyees as of March 11 2026.

Today ALPS has the market capitalization of 168.06M USD.